Aurinia Pharmaceuticals Inc (AUPH)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.11B
Last updated: Nov 17, 2026 at 11:04 AM ET
Aurinia Pharmaceuticals Inc (AUPH) Stock Forecast
Analysts expect Aurinia Pharmaceuticals (AUPH) to earn $0.97 per share in the fiscal year ending Dec 31, 2026, on revenue of $330.13M. Of 7 analysts, 5 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.29, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 71% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 5 | 71.4% |
| Hold | 2 | 28.6% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 19.6% and revenue estimates rise 16.8%.
- Fiscal year ending Dec 31, 2026
- $0.97
- EPS consensus, revenue $330.13M
- Fiscal year ending Dec 31, 2027
- $1.16
- EPS consensus, revenue $385.69M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.97 | $0.93 to $1.00 | 5 | $330.13M | $329.00M to $331.31M | 5 |
| Dec 31, 2027 | $1.16 | $0.68 to $1.63 | 5 | $385.69M | $360.00M to $461.12M | 6 |
Quarterly Estimates
The EPS consensus falls from $0.22 for the quarter ending Dec 31, 2026 to $0.19 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.22 | $0.17 to $0.25 | 7 | $87.27M | $82.71M to $91.02M | 8 |
| Mar 31, 2027 | $0.19 | $0.17 to $0.21 | 2 | $82.95M | $80.90M to $85.00M | 2 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 6 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 2 |
| Fiscal year ending Dec 31, 2027 | 1 | 4 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 2.1% from $0.95.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.97 | $0.95 | $0.94 | $0.94 | $0.95 | +2.1% |
| Fiscal year ending Dec 31, 2027 | $1.16 | $1.17 | $1.07 | $1.07 | $1.11 | +4.8% |
| Quarter ending Mar 31, 2027 | $0.19 | $0.19 | $0.17 | $0.17 | N/A | N/A |
Frequently Asked Questions About AUPH
What is the AUPH stock forecast?
Consensus analyst estimates put Aurinia Pharmaceuticals's EPS at $0.97 for the fiscal year ending Dec 31, 2026, on revenue of $330.13M. The consensus rating from 7 analysts is Buy.
How do analysts rate AUPH stock?
Of 7 analysts covering Aurinia Pharmaceuticals, 0 rate it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from AUPH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.97, with estimates from $0.93 to $1.00 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.16, with estimates from $0.68 to $1.63 from 5 analysts.
What revenue do analysts expect from Aurinia Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $330.13M, with estimates from $329.00M to $331.31M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $385.69M, with estimates from $360.00M to $461.12M.
How many analysts cover AUPH?
7 analysts rate Aurinia Pharmaceuticals stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
AUPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors